Free Trial

HLS Therapeutics Q1 2024 Earnings Report

HLS Therapeutics logo
C$3.99 +0.02 (+0.50%)
As of 01/17/2025 04:00 PM Eastern

HLS Therapeutics EPS Results

Actual EPS
-C$0.26
Consensus EPS
-C$0.25
Beat/Miss
Missed by -C$0.01
One Year Ago EPS
N/A

HLS Therapeutics Revenue Results

Actual Revenue
$16.82 million
Expected Revenue
$19.61 million
Beat/Miss
Missed by -$2.79 million
YoY Revenue Growth
N/A

HLS Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

HLS Therapeutics Earnings Headlines

Optimistic Buy Rating for HLS Therapeutics Despite Revenue Challenges
Outperform BTC without owning any crypto?
I want to let you in on what may be the hottest crypto discovery of all time… One that has NOTHING to do with creating a crypto wallet or touching ANY risky coin for that matter. Instead, it’s a way that could let regular folks like you and me target 10X the possible results you’d expect from buying Bitcoin … in just a fraction of the time It sounds nuts… trust me I know that… But just as I would hate for you to jump into any risky crypto asset… That’s exactly how I would hate for you to miss out on what could be a safer and better way to benefit from the crypto bull run of 2024. Which is why I’m giving you an opportunity to get all the details of this iconic crypto discovery with you for the first time ever… completely free…
See More HLS Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HLS Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HLS Therapeutics and other key companies, straight to your email.

About HLS Therapeutics

HLS Therapeutics (TSE:HLS), a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.

View HLS Therapeutics Profile

More Earnings Resources from MarketBeat